RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to ch…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered killer cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial is testing a new therapy called CD19 t-haNK, which uses specially engineered natural killer cells to target and destroy cancer cells. It is being tested alone and with the drug rituximab in 10 adults with B-cell non-Hodgkin lymphoma that has come back or no…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune cell combo targets hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment s…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for tough lymphoma: experimental drug IMV101 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called IMV101 in 30 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the …
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New injection shows promise for tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hard-to-treat lymphoma: first human trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental cell therapy takes aim at stubborn blood cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental immune cell therapy called GT719 in 34 adults with relapsed or refractory CD19-positive B-cell blood cancers (certain leukemias and lymphomas). The treatment uses specially engineered cells to target and destroy cancer cells. The …
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New injection could train your body to fight cancer from within
Disease control Recruiting nowThis early-phase trial tests a new drug called ZZSW-01 in 6 people with B-cell blood cancers that have come back or not responded to other treatments. The drug is a special particle that carries instructions for the body to make its own cancer-fighting cells. The main goal is to …
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC